Effects of Anti-Fibrotic Drugs on Transcriptome of Peripheral Blood Mononuclear Cells in Idiopathic Pulmonary Fibrosis

Daisuke Ishii,Takeshi Kawasaki,Hironori Sato,Koichiro Tatsumi,Takuro Imamoto,Keiichiro Yoshioka,Mitsuhiro Abe,Yoshinori Hasegawa,Osamu Ohara,Takuji Suzuki

DOI: https://doi.org/10.3390/ijms25073750

IF: 5.6

2024-03-29

International Journal of Molecular Sciences

Abstract:Two anti-fibrotic drugs, pirfenidone (PFD) and nintedanib (NTD), are currently used to treat idiopathic pulmonary fibrosis (IPF). Peripheral blood mononuclear cells (PBMCs) are immunocompetent cells that could orchestrate cell–cell interactions associated with IPF pathogenesis. We employed RNA sequencing to examine the transcriptome signature in the bulk PBMCs of patients with IPF and the effects of anti-fibrotic drugs on these signatures. Differentially expressed genes (DEGs) between "patients with IPF and healthy controls" and "before and after anti-fibrotic treatment" were analyzed. Enrichment analysis suggested that fatty acid elongation interferes with TGF-β/Smad signaling and the production of oxidative stress since treatment with NTD upregulates the fatty acid elongation enzymes ELOVL6. Treatment with PFD downregulates COL1A1, which produces wound-healing collagens because activated monocyte-derived macrophages participate in the production of collagen, type I, and alpha 1 during tissue damage. Plasminogen activator inhibitor-1 (PAI-1) regulates wound healing by inhibiting plasmin-mediated matrix metalloproteinase activation, and the inhibition of PAI-1 activity attenuates lung fibrosis. DEG analysis suggested that both the PFD and NTD upregulate SERPINE1, which regulates PAI-1 activity. This study embraces a novel approach by using RNA sequencing to examine PBMCs in IPF, potentially revealing systemic biomarkers or pathways that could be targeted for therapy.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The paper aims to explore the effects of antifibrotic drugs on the transcriptome of peripheral blood mononuclear cells (PBMCs) in patients with idiopathic pulmonary fibrosis (IPF) and to identify potential systemic biomarkers or therapeutic targets.

Specifically, the study compared the transcriptome characteristics of PBMCs between IPF patients and healthy controls using RNA sequencing technology and analyzed the effects of two antifibrotic drugs—pirfenidone (PFD) and nintedanib (NTD)—on the PBMCs transcriptome before and after treatment. The main findings include:

1. **Differences between IPF patients and healthy controls**:
- In IPF patients, compared to healthy controls, there were multiple differentially expressed genes (DEGs) mainly involving changes in fatty acid elongation, calcium signaling pathways, and other aspects.

2. **Effects of pirfenidone (PFD)**:
- After PFD treatment, the expression of certain genes in PBMCs changed, particularly downregulating genes related to wound healing (e.g., COL1A1) and upregulating genes that inhibit plasminogen activation (e.g., SERPINE1).

3. **Effects of nintedanib (NTD)**:
- After NTD treatment, changes in gene expression in PBMCs were also observed, especially upregulating genes related to fatty acid elongation (e.g., ELOVL6) and p53 signaling pathways (e.g., SERPINE1), and downregulating genes related to insulin secretion pathways.

Through these analyses, the study revealed the mechanisms of PBMCs in the pathological process of IPF and provided clues for further exploration of new therapeutic strategies.